Goldman Sachs Significantly Raises the Price Target for Novo Nordisk – Wegovy Pill Comes into Focus
Reading Time: 2 minutes
Goldman Sachs provides fresh buying arguments for Novo Nordisk. The US investment bank has significantly raised the price target for the Danish pharmaceutical company from DKK 352 to DKK 436 and confirmed the rating of Buy. Analyst James Quigley sees the new Wegovy pill as a massive short-term catalyst for sentiment and results. The main driver: "Oral Wegovy" as a catalyst for 2026 At the center of the optimistic assessment is the expectation that a two-stage news and demand catalyst will build around the pill in 2026. This follows key...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
